Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — NEPHROS INC

Accession: 0001493152-26-050233

Filed: 2026-11-05

Period: 2026-08-06

CIK: 0001196298

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001196298

0001196298

2026-08-06

2026-08-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 6, 2026

NEPHROS,

INC.

(Exact

name of Registrant as Specified in its Charter)

Delaware

001-32288

13-3971809

(State

or other jurisdiction of

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification No.)

380

Lackawanna Place, South

Orange, New

Jersey 07079

(Address

of principal executive offices, including ZIP code)

(201)

343-5202

(Registrant’s telephone number, including area code)

n/a

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, $0.001 par value

NEPH

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results

of Operations and Financial Condition.

On

November 5, 2026, Nephros, Inc. (the “Company”) issued a press release in which it disclosed its financial results for the

three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1.

Pursuant

to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this

Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of

1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated

by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth

by specific reference in such filing regardless of any general incorporation language.

Item 9.01. Financial

Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Nephros, Inc. Press Release, dated November 5, 2026.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by

the undersigned hereunto duly authorized.

Nephros, Inc.

Dated:

November 5, 2026

By:

/s/

Judy Krandel

Judy

Krandel

Chief

Financial Officer

EX-99.1

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call: 201 343 5202

nephros.com

Nephros

Announces Strong Third Quarter 2026 Financial Results

Year

Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended September 30,

2026.

SOUTH

ORANGE, NJ, November 5, 2026 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions

to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2026.

Financial

Highlights

● Net

revenue increased 18% to $5.6 million, compared to $4.8 million in the third quarter of 2025

● Net

income was $0.5 million, compared to net income of $0.3 million in the third quarter of 2025

● Adjusted

EBITDA was $0.6 million, compared to $0.4 million in the third quarter of 2025

“The

third quarter of 2026 continued the strong momentum we have built across Nephros,” said Robert Banks, President and Chief Executive

Officer of Nephros. “Net revenue increased approximately 18% over the prior-year quarter to $5.6 million, following the record

$6.0 million we reported in the second quarter. Importantly, we continued to translate that growth into improved profitability, generating

net income of approximately $0.5 million and Adjusted EBITDA of approximately $0.6 million. Our performance through the first nine months

of the year reinforces our confidence in the underlying strength and durability of the business.”

Banks

continued, “One of the most encouraging indicators during the quarter was the continued expansion of our customer base. We added

approximately 31 new customer sites in the third quarter, bringing our active installed base to a record 1,766 sites. Healthcare remains

at the core of Nephros, representing approximately 64% of new sites added during the quarter, while approximately 17% came from commercial

and industrial customers and the remainder represented a diverse mix of government, military, hospitality, residential, retail and other

applications. This breadth is important. It demonstrates that the value of our filtration technology is increasingly being recognized

across applications beyond our traditional healthcare markets while we further expand our presence within healthcare. We continue to

leverage emerging industry standards, regulatory developments, and market intelligence to identify unmet needs, inform strategic priorities,

and support expansion into new applications and markets.”

Banks

added, “We are also seeing our strategy evolve beyond products alone. During the quarter, the Nephros Water Institute continued

a strong series of educational webinars, strengthening what we believe is becoming an important third pillar of our business alongside

products and service. Education allows us to engage customers and industry professionals around emerging water-quality challenges, share

the expertise we have developed over many years, and build relationships well before a filtration decision is made. We plan to deepen

our investment in education as a driver of commercial growth and market development. We believe educational programming increases awareness

of water safety challenges and available solutions, generates qualified leads, and sustains engagement with prospective customers throughout

the sales cycle, supporting conversion and product adoption. We further believe the combination of differentiated products, service capabilities

and education increasingly distinguishes Nephros in the markets we serve.”

Banks

concluded, “As we enter the final quarter of 2026, our focus remains on execution. We have grown trailing twelve-month revenue

to more than $21 million, expanded our active customer base, remained profitable, and continued investing in the products, services and

capabilities that we believe can support the next stage of growth. Competition continues to evolve and the broader economic environment

remains uncertain, but we believe Nephros is entering the final months of the year from a position of strength. Our objective is simple:

finish 2026 strong and continue building a larger, more predictable and more valuable company for our shareholders.”

1

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call: 201 343 5202

nephros.com

Financial

Performance for the Quarter Ended September 30, 2026

Net

revenue for the three months ended September 30, 2026, and 2025 was $5.6 million and $4.8 million, respectively, an increase of 18%.

This increase was driven primarily by increased product revenue from programmatic growth, which grew by 8% over the same period in 2025

as well as significant growth in emergency response revenue. In addition, the company reported growth in service revenue.

Cost

of goods sold for the third quarter of 2026 was $2.3 million, compared with $1.8 million in the third quarter of 2025, an increase of

26%.

Gross

margin for the third quarter of 2026 was 58%, compared with 61% in the third quarter of 2025. The decrease of approximately three percentage

points was primarily attributable to higher inventory shipping and handling costs, including tariff expense, and growth in service revenue,

which yields lower gross margins than product sales.

Selling,

general and administrative expenses for the third quarter of 2026 were approximately $2.4 million, compared with $2.2 million in 2025,

an increase of 9% due to increases in headcount and an increase in professional fees.

Research

and development expenses for the third quarter of 2026 were approximately $331,000, compared with $338,000 in the third quarter of 2025,

a decrease of 2%.

Depreciation

and amortization expenses for the third quarter of 2026 were approximately $29,000, compared with approximately $34,000 in the third

quarter of 2025.

Net

income for the third quarter of 2026 increased to $0.5 million, compared with $0.3 million during the same period in 2025.

Adjusted

EBITDA for the third quarter 2026 increased to approximately $0.6 million, compared with approximately $0.4 million in the third quarter

of 2025.

Financial

Performance for the Nine Months Ended September 30, 2026

Net

revenue for the nine months ended September 30, 2026, and 2025 was $16.9 million, and $14.1 million respectively, an increase of 20%.

Core programmatic revenue grew by 19% over the same period in 2025. The increase in programmatic sales reflects strong reorders, and

a number of new active sites. In addition, service revenue experienced strong growth.

Cost

of goods sold for the nine months ended September 30, 2026 and 2025 was $6.5 million, and $5.2 million respectively, an increase of 26%.

Gross margin for the nine months ended September 30, 2026 was 61%, compared with 63% during the same period in 2025. The decrease was

primarily attributable to increased product costs due to the weakening of the U.S. dollar compared to the Euro, and rapid revenue growth

from commercial products offerings and services revenue, both of which yield lower gross margins than the infection control business.

However, gross margins significantly benefited from the recognition during the 2026 period of the IEEPA tariff refund of approximately

$0.6 million, which was recorded as a reduction of cost of goods sold during the nine months ended September 30, 2026. This refund reflects

tariffs paid by Nephros from April 2025 to February 2026. Approximately $0.3 million of this tariff refund corresponds to purchased inventory

that was converted to revenue in 2026. The remaining approximately $0.3 million of the refunded tariffs correspond to purchased inventory

that was converted to revenue in 2025, of which approximately $0.2 million corresponds to purchased inventory that was converted to revenue

in the nine months ended September 30, 2025.

2

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call: 201 343 5202

nephros.com

Selling,

general and administrative expenses for the nine months ended September 30, 2026 and 2025 were approximately $7.4 million, and $6.7 million

respectively, an increase of 10% primarily due to an increase in headcount and an increase in professional fees.

Research

and development expenses for the nine months ended September 30, 2026 and 2025 were $1.0 million and $0.9 million respectively.

Depreciation

and amortization expenses for the nine months ended September 30, 2026 and 2025 were approximately $87,000, and $108,000 respectively.

As

a result of the improved sales, net income for the nine months ended September 30, 2026 increased to $1.8 million compared to $1.1 million

during the same period in 2025.

Adjusted

EBITDA for the nine months ended September 30, 2026 increased to approximately $2.0 million, compared with approximately $1.4 million

in the same period of 2025.

As

of September 30, 2026, Nephros had cash and cash equivalents of approximately $4.5 million, compared to $5.4 million as of December 31,

2025, and remains debt free.

Adjusted

EBITDA Definition and Reconciliation to GAAP Financial Measures

Adjusted

EBITDA is calculated by taking net income calculated in accordance with generally accepted accounting principles (“GAAP”)

and excluding all interest-related expenses and income, tax-related expenses and income, and non-cash items, including depreciation,

amortization, non-cash inventory write-offs, and non-cash compensation. The following tables present a reconciliation of Adjusted EBITDA

to net income, the most directly comparable GAAP financial measure, for the third quarter of the 2026 fiscal year:

(unaudited)

Three Months Ended September 30,

2026

2025

(in $ thousands)

Net income

512

337

Adjustments:

Depreciation of property and equipment

11

12

Amortization of other assets

20

22

Interest expense

-

-

Interest income

(53 )

(41 )

Income taxes

-

3

Non-cash stock-based compensation

60

70

Non-cash inventory impairments

8

15

Adjusted EBITDA Income

558

418

(unaudited)

Nine Months Ended September 30,

2026

2025

(in $ thousands)

Net income

1,849

1,132

Adjustments:

Depreciation of property and equipment

34

42

Amortization of other assets

52

65

Interest expense

1

1

Interest income

(115 )

(85 )

Income taxes

13

12

Non-cash stock-based compensation

181

217

Non-cash inventory impairments

30

56

Adjusted EBITDA Income

2,045

1,440

3

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call: 201 343 5202

nephros.com

Nephros

believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends

relating to Nephros’ financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation or

as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes

significant expenses and income that are required by GAAP to be recognized in Nephros’ financial statements. In addition, Adjusted

EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are

excluded or included in determining Adjusted EBITDA. To compensate for these limitations, management presents Adjusted EBITDA in connection

with net income, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted

EBITDA to net income and not to rely on any single financial measure to evaluate the business.

Conference

Call Today at 4:30pm Eastern Time

Nephros

will host a conference call today at 4:30pm ET, during which management will discuss Nephros’ financial results and provide a general

business overview.

Participants

may dial into the call as follows:

Domestic access: 1 (646) 307-1963

International access: (800) 715-9871

Upon

joining, please ask to be joined into the Nephros conference call.

An

audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

Alternatively,

a replay of the call may be accessed until November 12, 2026 at 1-855-669-9658 or

1-412-317-0088 for international callers and entering replay access code: 8234499

About

Nephros

Nephros

is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration

products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the

needs of customers within healthcare and commercial markets, offering both proactive and emergency solutions for water management.

For

more information about Nephros, please visit nephros.com.

Forward-Looking

Statements

This

release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding

Nephros’ expected future business, revenue and gross margin growth and the timing of such growth, the drivers of our revenue growth,

the effect of new regulations on future revenue growth, Nephros’ ability to continue to grow its product and service offerings

beyond traditional healthcare markets, the expected competitive advantages and anticipated impact of new product and service offerings

and market expansions, and other statements that are not historical facts, including statements that may be accompanied by the words

“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”

“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”

“potential” or similar words. Actual results could differ materially from those described in these forward-looking statements

due to certain factors, including Nephros’ ability to further develop its sales organization and realize increased revenues, the

extent to which financial results based on emergency response sales can be outside Nephros’ control, the extent to which U.S. tariffs

may increase our expenses, inflationary factors and other economic and competitive conditions, the availability of capital when needed,

dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed

in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year

ended December 31, 2025, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has

filed or will file hereafter. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks

only as of the date of this release, and Nephros does not undertake any responsibility to update any forward-looking statements that

it makes, except as may be required by law.

Investor

Relations Contacts:

Kirin

Smith, President

PCG Advisory, Inc.

(646) 823-8656

ksmith@pcgadvisory.com

Robert

Banks, CEO

Nephros, Inc.

(201) 343-5202 x110

robert.banks@nephros.com

4

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call: 201 343 5202

nephros.com

NEPHROS,

INC.

BALANCE

SHEETS

(In

thousands, except share and per share amounts)

(Unaudited)

September 30, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$ 4,546

$ 5,400

Accounts receivable, net

3,583

2,414

Inventory

4,953

3,232

Prepaid expenses and other current assets

174

177

Total current assets

13,256

11,223

Property and equipment, net

72

106

Lease right-use-of assets

735

1,021

Intangible assets, net

294

318

Goodwill

759

759

License and supply agreement, net

139

164

Other assets

50

50

TOTAL ASSETS

$ 15,305

$ 13,641

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

850

914

Accrued expenses

1,133

1,462

Current portion of lease liabilities

426

391

Total current liabilities

2,409

2,767

Lease liabilities, net of current portion

348

672

TOTAL LIABILITIES

2,757

3,439

STOCKHOLDERS’ EQUITY:

Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025.

-

-

Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2026 and December 31, 2025; 10,870,004 and 10,644,268 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively

11

11

Additional paid-in capital

153,826

153,329

Accumulated deficit

(141,289 )

(143,138 )

TOTAL STOCKHOLDERS’ EQUITY

12,548

10,202

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$ 15,305

$ 13,641

5

Nephros, Inc.

380 Lackawanna Place

South Orange NJ 07079

Call: 201 343 5202

nephros.com

NEPHROS, INC.

STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Net revenue:

Product revenues

$ 5,431

$ 4,596

$ 16,172

$ 13,613

Service, royalty and other revenues

191

168

679

447

Total net revenues

5,622

4,764

16,851

14,060

Cost of goods sold

2,336

1,849

6,546

5,196

Gross margin

3,286

2,915

10,305

8,864

Operating expenses:

Selling, general and administrative

2,425

2,229

7,364

6,684

Research and development

331

338

1,043

944

Depreciation and amortization

29

34

87

108

Total operating expenses

2,785

2,601

8,494

7,736

Operating income

501

314

1,811

1,128

Other (expense) income:

Interest expense

-

-

(1 )

(1 )

Interest income

53

41

115

85

Other income (expense), net

(42 )

(15 )

(63 )

(68 )

Total other expense:

11

26

51

16

Income (loss) before income taxes

512

340

1,862

1,144

Income tax expense

-

(3 )

(13 )

(12 )

Net income

$ 512

$ 337

$ 1,849

$ 1,132

Net income per common share, basic

$ 0.05

$ 0.03

$ 0.17

$ 0.11

Net income per common share, diluted

$ 0.05

$ 0.03

$ 0.17

$ 0.10

Weighted average common shares outstanding, basic

10,863,253

10,612,012

10,790,982

10,604,300

Weighted average common shares outstanding, diluted

11,203,973

11,040,925

11,096,826

10,846,477

6

GRAPHIC

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (9375 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Aug. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 06, 2026

Entity File Number

001-32288

Entity Registrant Name

NEPHROS,

INC.

Entity Central Index Key

0001196298

Entity Tax Identification Number

13-3971809

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

380

Lackawanna Place

Entity Address, City or Town

South

Orange

Entity Address, State or Province

NJ

Entity Address, Postal Zip Code

07079

City Area Code

(201)

Local Phone Number

343-5202

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, $0.001 par value

Trading Symbol

NEPH

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration